Holocene

Predictive Oncology Reports Year End 2023 Financial Results and Provides Business Update

Retrieved on: 
목요일, 3월 28, 2024
Consultant, CRH, Ovarian cancer, Conference call, Conference, Survival, Science, Intelligence, Drug discovery, Webcast, BIO, Research, Holocene, UPMC, KOL, G&A, Call, GMP, UPMC Magee-Womens Hospital, Cloud computing, CLIA, Drug development, Machine learning, Marketing, Artificial intelligence, Cryptocurrency

The company reported a net loss of approximately $14 million on total revenue of approximately $1.8 million for the year ended December 31, 2023.

Key Points: 
  • The company reported a net loss of approximately $14 million on total revenue of approximately $1.8 million for the year ended December 31, 2023.
  • “Perhaps most notably, we announced last quarter that we successfully delivered the results of our first campaign with Cancer Research Horizons.
  • Revenues for the years ended December 31, 2023, and December 31, 2022, were primarily derived from its Eagan operating segment.
  • Conference call and webcast details:
    Predictive Oncology management will host an investor conference call and webcast on Monday, April 1st, at 8:30am EDT.

Healthier Choices Management Corp. Reports Fourth Quarter 2023 Financial Results and Full Year Fiscal 2023 Results

Retrieved on: 
수요일, 3월 27, 2024
OTC Markets Group, Holocene, Acquisition

HOLLYWOOD, FL, March 27, 2024 (GLOBE NEWSWIRE) -- Healthier Choices Management Corp. (OTC Pink: HCMC) today announced financial results for the fourth quarter and the twelve-months ended December 31, 2023.

Key Points: 
  • Fourth Quarter 2023 Results and Recent Highlights:
    Net sales from operations for the three-month period ended December 31, 2023, amounted to $15.9 million, compared to $12.3 million, an approximately $3.5 million and 29% increase versus the same period in 2022.
  • Net Loss from Operations for the three-month period ended December 31, 2023, amounted to approximately $9.4 million versus a $3.8 million loss for the same period last year.
  • Adjusted EBITDA for the fourth quarter amounted to a loss of $1.8 million versus a $3.3 million loss for the same period in 2022, an improvement of approximately $1.5 million.
  • The following table sets forth our Condensed Consolidated Statements of Operations for the three and twelve-months ended December 31, 2023 and 2022:

Evoke Pharma Reports Fourth Quarter and Full Year 2023 Financial Results

Retrieved on: 
목요일, 3월 14, 2024
Research, Certification, Quarter, Prevalence, Teva Pharmaceuticals, Gastrointestinal disease, Partnership, ACG, Metoclopramide, Patient, Pharmacy, Gastroparesis, Health care, Holocene, Prescription, Orange Book, Marketing, Gastroenterology, Woman, DDW, PBM, Hospital, Pharmaceutical industry

SOLANA BEACH, Calif., March 14, 2024 (GLOBE NEWSWIRE) -- Evoke Pharma, Inc. (NASDAQ: EVOK), a specialty pharmaceutical company focused primarily on treatments for gastrointestinal (GI) diseases with an emphasis on GIMOTI® (metoclopramide) nasal spray, today announced its financial results for the fourth quarter and full year ended December 31, 2023, and recent corporate developments.

Key Points: 
  • Our commercial team’s dedicated efforts yielded a 107% increase in year-over-year revenue,” stated Dave Gonyer, R.Ph., CEO of Evoke Pharma.
  • Research and development expenses totaled approximately $23,000 for the fourth quarter of 2023 compared with $27,000 for the fourth quarter of 2022.
  • For the fourth quarter of 2023 selling, general and administrative (SG&A) expenses were approximately $3.5 million compared with $2.3 million for the fourth quarter of 2022.
  • Total operating expenses for the fourth quarter of 2023 were approximately $3.6 million compared with $2.3 million for the same period of 2022.

Adicet Reports Fourth Quarter and Full Year 2023 Financial Results and Highlights Recent Company Progress

Retrieved on: 
화요일, 3월 19, 2024
Oncology, Health, Clinical Trials, Research, Science, Pharmaceutical, Biotechnology, ChromeOS, Administration, MCL, ASH, Protocol, Patient, Tumor microenvironment, Holocene, G&A, CD70, Cancer, Tropism, Renal cell carcinoma, NHL, IND, Drug, Mantle cell lymphoma, Research and development, Society, TGF, ATM, Safety, FDA, Lupus nephritis, Autoimmunity, Pharmaceutical industry

Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2023.

Key Points: 
  • Adicet Bio, Inc. (Nasdaq: ACET), a clinical stage biotechnology company discovering and developing allogeneic gamma delta T cell therapies for autoimmune diseases and cancer, today reported financial results and operational highlights for the fourth quarter and year ended December 31, 2023.
  • In December 2023, the FDA cleared the Company’s IND application for ADI-001 in lupus nephritis.
  • Adicet plans to initiate a Phase 1 study to evaluate the safety and efficacy of ADI-001 in lupus nephritis during the second quarter of 2024.
  • Preliminary clinical data from the trial are expected in the fourth quarter of 2024 or first quarter of 2025, pending study site activation progression and patient enrollment.

The Anthropocene epoch that isn’t – what the decision not to label a new geological epoch means for Earth’s future

Retrieved on: 
금요일, 4월 5, 2024
Holocene, Environment, Geology, Acceleration, Travel, Climate, Social media, RSS, University, Anthropocene, Human, Music, Geography, The Conversation, Nobel

Then in March, an international panel of scientists formally rejected the proposal for a new Anthropocene epoch.

Key Points: 
  • Then in March, an international panel of scientists formally rejected the proposal for a new Anthropocene epoch.
  • He says the change has been “extraordinarily rapid”, particularly since the mid-20th century, a time known as the great acceleration.
  • An Anthropocene Working Group was established in 2009 to explore whether the Anthropocene should be declared an official geological epoch, different to the Holocene, which began around 11,700 years ago.
  • A new epoch would mean that a distinct change could be seen in the fossil record with geological strata distinctive from those below and above it.

Lucas GC Limited (NASDAQ: LGCL) Successfully Listed on NASDAQ With Appealing Valuation of the "AI+PaaS" Theme

Retrieved on: 
수요일, 3월 6, 2024
RMB, Internet, Holocene, Prospectus, Ministry, Education, Dartmouth College, Investment, PS, Growth, Digital, Data analysis, Database, VCS, CFA, Hewlett Foundation, Frost, Western Digital, Stanford University, IPO, GPT, Sun Microsystems, Platform as a service, Capital gain, UCLA, China Securities Regulatory Commission, Haier, Information technology, Research, Cryptocurrency

Lucas' achievements are rarely seen among the recently listed companies on NASDAQ.

Key Points: 
  • Lucas' achievements are rarely seen among the recently listed companies on NASDAQ.
  • 51Job which is 30% owned by Recruit Holding of Japan, is the second largest shareholder of Lucas which demonstrates its endorsement of Lucas' business model and roadmaps.
  • For other strategic investors, the involvement of domestic AI unicorn BeagleData serves as a notable validation of the Company's AI technology.
  • Haier Group's investment brings forth a range of enhancements to the company's corporate governance and extends multidimensional industry resource supports to Lucas.

Security Journey Releases Secure Coding Training Program Guide to Address Industry Needs and Regulatory Requirements

Retrieved on: 
수요일, 3월 6, 2024
Workload, Holocene, Guide, CISA, Research, Culture, White, Walking, Organization, Security (finance), Face, Medical device

Pittsburgh, PA, March 06, 2024 (GLOBE NEWSWIRE) -- Today, best-in-class application security education company, Security Journey, releases its Ideal Secure Coding Training Program Guide to support organizations in building out a long-term, sustainable approach to application security.

Key Points: 
  • Pittsburgh, PA, March 06, 2024 (GLOBE NEWSWIRE) -- Today, best-in-class application security education company, Security Journey, releases its Ideal Secure Coding Training Program Guide to support organizations in building out a long-term, sustainable approach to application security.
  • The 14-page, 7 step Guide shares actionable best practices for planning, implementing, and maintaining an effective secure code training program, complete with guidance around gaining executive buy-in and utilizing gamification.
  • The Guide also includes sample training plans, purpose-built to help admins ensure their program delivers quick impact on knowledge gain and proof of compliance and eases their workload.
  • This Program Guide is designed to make the commitment to a continuous training program pain-free so that organizations can quickly improve skills and foster a culture of security awareness.”
    Topics covered in the Guide include:

Okeanis Eco Tankers Corp. – Unaudited Condensed Financial Statements for the Fourth Quarter and Twelve Month Period of 2023

Retrieved on: 
목요일, 2월 29, 2024
NOK, Holocene, Suezmax, TCE, CSDR, ECO, Sale, Calendar, Exercise, OET, Euronext, Webcast, Bank statement, CMB, VLCC

ATHENS, Greece, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Okeanis Eco Tankers Corp. (“OET” or “Company”) (NYSE:ECO / OSE:OET) today reported unaudited condensed financial statements for the fourth quarter and twelve month period of 2023, which are attached to this press release.

Key Points: 
  • ATHENS, Greece, Feb. 29, 2024 (GLOBE NEWSWIRE) -- Okeanis Eco Tankers Corp. (“OET” or “Company”) (NYSE:ECO / OSE:OET) today reported unaudited condensed financial statements for the fourth quarter and twelve month period of 2023, which are attached to this press release.
  • Adjusted profit and Adjusted earnings per share (non-IFRS measures*) for the period of $20.4 million or $0.63 per basic & diluted share.
  • Fleetwide daily TCE rate of $45,400 per operating day; VLCC and Suezmax TCE rates of $45,200 and $45,600 per operating day, respectively.
  • OET will be hosting a conference call and webcast at 13:30 CET on Thursday February 29, 2024, to discuss the Q4 2023 results.

Crinetics Pharmaceuticals Reports Fourth Quarter and Full Year 2023 Financial Results and Provides Corporate Update

Retrieved on: 
수요일, 2월 28, 2024
ENDO, SAN, Congenital adrenal hyperplasia, Holocene, Carcinoid syndrome, Research, Entrepreneurship, Investment, FDA, Food, Webcast, Growth, Graves' ophthalmopathy, Primary hyperparathyroidism, PTH1R, Somatostatin, Conference, Endocrinology, Safety, TSH, Patient, CAH, Trial of the century, NDA, PHPT, Pharmaceutical industry

SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the fourth quarter and full year ended December 31, 2023.

Key Points: 
  • ET Today
    SAN DIEGO, Feb. 28, 2024 (GLOBE NEWSWIRE) -- Crinetics Pharmaceuticals, Inc. (Nasdaq: CRNX) today reported financial results for the fourth quarter and full year ended December 31, 2023.
  • We also expect full results from our Phase 2 study in carcinoid syndrome in the first half of this year.
  • In December 2023, Crinetics reported an initial analysis of data from a subset of 27 patients.
  • Earlier today, February 28, 2024, Crinetics announced a private placement equity financing for gross proceeds of approximately $350 million.

Brightcove Announces Financial Results for Fourth Quarter and Fiscal Year 2023

Retrieved on: 
목요일, 2월 22, 2024
Software, Networks, Entertainment, Internet, Apps, Applications, Technology, General Entertainment, Digital Marketing, TV and Radio, Marketing, Audio, Video, Communications, CFO, Holocene, MLS, AI, Analytics, Growth, Johnson & Johnson, Ford Motor Company, HubSpot, Dropbox, Google Drive, BCOV, GAAP, MotoAmerica, Metadata, Organization, Emmy Awards, Public expenditure, Eastern Time Zone, DeBevoise, Salesforce, Marketo, Inc., Pinterest, Depreciation, Partnership, Video game

Brightcove Inc. (Nasdaq: BCOV), the world’s most trusted streaming technology company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023.

Key Points: 
  • Brightcove Inc. (Nasdaq: BCOV), the world’s most trusted streaming technology company, today announced financial results for the fourth quarter and fiscal year ended December 31, 2023.
  • Loss from operations was $2.3 million for the fourth quarter of 2023, compared to loss from operations of $6.0 million for the fourth quarter of 2022.
  • Net loss was $2.5 million, or a loss of $0.06 per diluted share, for the fourth quarter of 2023.
  • Cash flow provided by operations was $4.2 million for the fourth quarter of 2023, compared to cash flow provided by operations of $5.7 million for the fourth quarter of 2022.